Renaxen 5 mg (Axitinib) – 60 Tablets

Renaxen 5 mg is a tablet containing Axitinib INN 5 mg. Axitinib is an oral tyrosine kinase inhibitor. Its main therapeutic targets are VEGFR-1, VEGFR-2, and VEGFR-3. These receptors play an important role in angiogenesis, the process through which tumors form new blood vessels. By blocking VEGF receptor signaling, Axitinib can View productreduce the blood-vessel growth that supports tumor development. The National Cancer Institute describes axitinib as a tyrosine kinase inhibitor and antiangiogenesis agent used alone or with other medicines for advanced renal cell carcinoma. Renaxen is therefore best understood as an Axitinib-based targeted therapy for advanced kidney cancer.